Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the safety, tolerability and pharmacokinetics of Ig NextGen 10% in
patients with primary immune deficiency currently being treated with Intragam P. Eligible
patients will switch from 3 to 4 weekly intravenous Intragam P therapy to receive seven
cycles of Ig NextGen 10% treatment administered intravenously at three- to four-weekly
intervals. Patients will be monitored on the study for up to 36 weeks.